Wadih Chakkour, MD
Pulmonary Disease · Springfield, ORNPI 1588001895
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,362 of the $1,521 with a category attached, or 89.5%. It is spread thinly across 10 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $918 and has fallen 66.4% since, to $309 in 2021.
Across 39 payments — averaging $39.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$305
- AstraZeneca$282
- GSK$221
- Boehringer Ingelheim$189
- Insmed, Inc.$165
- AbbVie$97
- plus $262 from 4 others
What the payments were for
- Food & beverage$1,36290%
- Education$15910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $305 |
| AstraZeneca(2 entities) | 6 | $282 |
| GSK | 10 | $221 |
| Boehringer Ingelheim | 2 | $189 |
| Insmed, Inc. | 5 | $165 |
| AbbVie | 2 | $97 |
| Merck | 1 | $94 |
| CSL Behring | 1 | $74 |
| United Therapeutics Corporation | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$120
How this compares
$1,521 in reported general payments places this provider in the 65th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 51 | $58,439 |
| Spiriva HandihalerTiotropium Bromide | 47 | $51,237 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $31,161 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $19,780 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $17,432 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $13,922 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $8,359 |
| Arnuity ElliptaFluticasone Furoate | 15 | $8,259 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,872 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $6,433 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $4,425 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $3,111 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,843 |
| Azithromycin | 59 | $507 |
| Montelukast Sodium | 48 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $189 | $72,36167 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta, Breo Ellipta | $221 | $55,65280 claims |
| AstraZenecaSymbicort | $282 | $19,78038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Springfield
- Khuram AmeenSpringfield$6K
- Stephen YauPortland$984K
- Jeremy FeldmanBend$456K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Matthew HegewaldBend$94K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.